Table of Contents Author Guidelines Submit a Manuscript
Advances in Urology
Volume 2013, Article ID 584678, 8 pages
Clinical Study

The Effects of Chlormadinone Acetate on Lower Urinary Tract Symptoms and Erectile Functions of Patients with Benign Prostatic Hyperplasia: A Prospective Multicenter Clinical Study

1Department of Urology, Nara Medical University, 840 Shijo-cho Kashihara, Nara 634-8522, Japan
2Department of Biostatistics, University of Tokyo, Tokyo 113-0033, Japan
3Department of Urology, Gunma University Graduate School of Medicine, Maebashi 371-8511, Japan
4Department of Urology, Showa University School of Medicine, Tokyo 142-8555, Japan
5Department of Urology, Kinki University Faculty of Medicine, Osaka-Sayama 589-8511, Japan
6Department of Urogenital Surgery, Kanazawa Medical University, Kanazawa 920-0293, Japan
7Department of Urology, Ibaraki Prefectural Central Hospital and Cancer Center, Kasama 309-1793, Japan
8Department of Urology, Furuya Hospital, Kitami 090-0065, Japan
9Boku Clinic of Urology and Nephrology, Habikino 583-0856, Japan

Received 7 March 2013; Accepted 20 April 2013

Academic Editor: Martin Marszalek

Copyright © 2013 Kiyohide Fujimoto et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Purpose. To evaluate the effects of chlormadinone acetate (CMA), progesterone-derived antiandrogen, on lower urinary tract symptoms (LUTS) and erectile functions of benign prostatic hyperplasia (BPH). Methods. A multicenter, single-cohort prospective study was conducted. A total of 114 patients received CMA for 16 weeks. The endpoints were changes in International Prostate Symptom Scores (IPSS), IPSS-QOL, International Index of Erectile Function-5, prostate volume, and residual urine volume. Results. Significant improvements were observed in IPSS from week 8 to week 48 (32 weeks after treatment). IPSS-QOL improvements were also significant from week 8 to week 48. increased to a maximum at Week 16 and remained elevated throughout the study. Moreover, a decrease of 25% in prostate volume was observed at Week 16. IPSS, QOL, and Qmax changes during the study were not different between the previously treated and untreated patients. IPSS storage subscore changes differed between the age groups. Few severe adverse reactions were observed, except for erectile dysfunction. Conclusions. CMA rapidly and significantly reduced prostate volume and improved voiding and storage symptoms and QOL. Our results suggest that CMA is safe and beneficial, especially for elderly patients with LUTS associated with BPH.